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Abstract
Background Pulmonary vasodilators in general and
prostacyclin therapy in particular, have markedly improved
the outcome of patients with pulmonary arterial hyperten-
sion (PAH). As endothelial dysfunction is a key feature of
PAH, and as endothelial progenitor cells (EPC) may con-
tribute to vascular repair in PAH, we suspected that pros-
tacyclin therapy might enhance EPC numbers and
functions. In the present study, objectives were to deter-
mine whether EPC may contribute to vasodilator treatment
efﬁcacy in PAH.
Methods We quantiﬁed CD34? cells, CFU-Hill and
ECFC (endothelial colony forming cells) in peripheral
blood from children with idiopathic PAH (n = 27) or PAH
secondary to congenital heart disease (n = 52). CD34?
were enumerated by ﬂow cytometry, CFU-Hill and ECFC
by a culture assay. ECFC grown ex vivo were tested for
their angiogenic capacities before and after prostacyclin
analog therapy (subcutaneous treprostinil).
Results ECFC counts were signiﬁcantly enhanced in the 8
children treated with treprostinil, while no change was
observed in children receiving oral therapy with endothelin
antagonists and/or PDE5 inhibitors. CD34? cell and CFU-
Hill counts were unaffected. ECFC from patients treated
with treprostinil had a hyperproliferative phenotype and
showed enhanced angiogenic potential in a nude mouse
preclinical model of limb ischemia.
Conclusions ECFC may partly mediate the clinical ben-
eﬁts of prostanoids in pulmonary arterial hypertension.
Keywords Pulmonary hypertension  Congenital heart
disease  Vasodilator treatment  Treprostinil  EPC
Introduction
Pulmonary vascular disease (PVD) can cause pulmonary
arterial hypertension (PAH), usually leading to right heart
failure and death if left untreated [1]. Endothelial cell
dysfunction is a hallmark of both idiopathic PAH and PAH
secondary to congenital heart disease [2–4].
A role of endothelial progenitor cells (EPC) in vascular
repair and new vessel formation has been described [5–7].
EPC mobilized from bone marrow and/or resident locally in
the lung, are thought to be important in maintaining vas-
cular homeostasis; and there is a growing interest in the
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Experimental and clinical studies have examined the pos-
sible contribution of EPC to the pathogenesis of PAH, but
reported EPC counts in patients with pulmonary hyperten-
sion have been inconsistent [8–11]. Several types of EPC
are deﬁned, depending on the method used (ﬂow cytometry
or culture) and their characteristics. At least two popula-
tions of EPC have been described [5, 12]. ‘‘Early’’ EPC are
spindle-shaped and express both endothelial and leukocyte
markers. Quantiﬁcation of this cell population, as described
by Hill, utilizes a commercial kit that identiﬁes so-called
‘‘CFU-Hill’’ [13]. The number of CFU-Hill in peripheral
blood has been reported to correlate inversely with cardio-
vascular risk factors [13]. ‘‘Late’’ EPC, also called endo-
thelial colony-forming cells (ECFC) [7, 14], develop after
1–3 weeks of culture and have the characteristics of pre-
cursor cells committed to the endothelial lineage. Both EPC
subtypes have therapeutic potential but in vivo, cells that
merge into neovessels have an ECFC phenotype [6, 7].
EPC transplantation was recently shown to improve
pulmonary hypertension in a rat model [15, 16], while
Wang et al. [17] found that EPC transplantation improved
exercise capacity and pulmonary hemodynamics in patients
with idiopathic PAH , and a contemporary open-label, non-
randomized pilot trial showed that EPC transplantation led
to signiﬁcant improvements in exercise capacity, New
York Heart Association functional class, and pulmonary
hemodynamics in children with idiopathic PAH [18].
‘‘Pulmonary vasodilator’’ therapy has greatly improved
the prognosis of patients with PAH [19, 20]. In particular,
parenteral prostacyclin improves the outcome of patients
with PVD, not only by inducing pulmonary vasodilation
but also by altering pulmonary vascular structure and
function during long-term administration. Intravenous
prostacyclin is currently recommended for patients of all
ages with WHO functional class IV disease, and as add-on
therapy for patients remaining in class III despite correctly
dosed treatment with endothelin-receptor antagonists
(ERA) and phosphodiesterase-5 inhibitors (PDE5) [19, 20].
Subcutaneous treprostinil, a parenteral prostanoid, is
sometimes preferred to an intravenous prostacyclin in
children, especially to avoid the long-term risks associated
with chronic intravenous therapy.
Given the possible relationship between EPC and
treatment efﬁcacy, we therefore examined the impact of
treprostinil therapy on the number and functional capacity
of EPC in children with advanced PAH.
Patients and methods
Study population (Table 1)
This prospectively designed study was aimed at deter-
mining the numbers and functional capacities of EPC
before and after vasodilator treatment, and especially after
treprostinil therapy. Blood samples were collected during
outpatient visits from patients already on single- or dual-
agent therapy. In the 8 treprostinil-treated patients, EPC
were studied before treatment initiation, 2 and 5 days later
and monthly thereafter.
The study was approved by the institutional ethics com-
mittee of Necker-Enfants Malades hospital, and the parents
gave their signed informed consent. Fifty-two consecutive
patientswithCHDandPAH,and27consecutivepatientswith
idiopathic PAH (Table 1) were enrolled between February
2008 and 2010. The 27 patients with idiopathic PAH had a
median age of 6 years. Among the patients with CHD, 28
(median age 2 years) had reversible PAH, as deﬁned by nor-
mal pulmonary pressure 6 months after surgery, while 24
(median age 8 years) had irreversible PAH, based on persis-
tently elevated pulmonary artery pressure and pulmonary
vascular resistance. Children with irreversible PAH were
older than children with reversible and idiopathic PAH
(P = 0.01andP = 0.06,respectively)andhadloweroxygen
saturation values (P = 0.02 and P = 0.0008, respectively).
Pulmonary artery pressure was similar in the three groups
(Table 1).PatientswithfamilialPAHassociatedwithBMPR2
mutations were not included in this study, because of a pos-
sibleimpactofBMPonEPCangiogenicproperties[6,21,22].
Table 1 Characteristics of the patients
Reversible
PAH
(n = 28)
Irreversible
PAH
(n = 22)
Idiopathic PAH
(n = 27)
P value reversible
versus irreversible
PAH
P value reversible
versus
Idiopathic PAH
P value irreversible
versus
Idiopathic PAH
Age (y) 2 (2.7–6.5) 8 (6.1–16.4) 6 (4.5–8.4) 0.01* 0.16 0.06
Saturation (%) 96 (89.2–95.3) 86 (79.8–91.3) 97.5 (93.5–98.4) 0.02* 0.07 0.0008*
Mean PAP 55 (50–66.2) 60 (50.3–66.5) 53 (46–56.5) 0.13 0.15 0.95
Data are expressed as medians and conﬁdence intervals (95%CI). Baseline characteristics were compared with Wilcoxon’s rank sum test for non
normally distributed variables (age) and Student’s unpaired test otherwise
* P\0.05, reversible versus irreversible PAH
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123Indeed, BMPR2 mutations have been reported to affect both
early [23] and late EPC, the latter showing a hyperprolifera-
tive phenotype and an impaired capacity to form vascular
networks [22]. Because of adverse effects reported with IV
epoprostenol and inhaled prostanoids, subcutaneous trepros-
tinilwasusedasﬁrst-lineadd-ontherapyfor8youngchildren
who deteriorated while receiving combined oral therapy with
anendothelinreceptoragonistandaPDE5inhibitor.Threeof
them had idiopathic PAH and ﬁve patients had PAH associ-
ated with a congenital heart defect. The decision to add sub-
cutaneous tresprostinil was based on their clinical status
(change in functional class), including right ventricular dys-
function (hepatomegaly, increase in tricuspid regurgitation
volume,dilationofhepaticveinsandtheinferiorvenacava)in
seven patients. Two of them also had syncope. One patient in
functional class II had severe complications associated with
the central venous line used to deliver epoprostenol. All the
patients had right heart catheterization prior to treprostinil
treatment. Treprostinil administration was initiated at hospi-
tal, through a subcutaneous catheter in the outer leg. All the
patientsinitiallyreceivedaﬁxeddoseof1.25 ng/kg/min.The
dosewasthendailyincreasedby1.25 ng/kg/min,reachingan
average of 20 ng/kg/min at hospital discharge. During tre-
prostinil treatment, site pain was evaluated every 6 h using
standard pain scales adapted to age. After hospital discharge
thetreprostinildosewasadjustedatmonthlyout-patientvisits
andreachedanaverageof40 ng/kg/min.Technicalassistance
was provided at home by specialized nurses trained in the
management of parenteral prostanoid therapy in PAH
patients. All patientshad experienced a clinical improvement
performed,foroldestchildrenby6MWT,andtheyallshowed
animprovementinoxygensaturationandfunctionalstatus,as
theywereallinfunctionalclassIorII.Inﬁvepatientswhohad
rightheartcatheterizationaftertreprostinil,pulmonaryarterial
pressure did not change but cardiac output increased and
pulmonary vascular resistance decreased.
Flow cytometric quantiﬁcation of CD34?
hematopoietic progenitor cells (HPC)
Circulating CD34? cells were counted by ﬂow cytometry
(FC500Cytometer;BeckmanCoulter,Villepinte,France)after
staining of whole blood with a ﬂuorescein isothiocyanate
(FITC)-labeledmonoclonalmouseantihumanCD45antibody,
a phycoerythrin (PE)-labeled monoclonal mouse antihuman-
CD34 antibody, and 7AAD (Stemkit
; Beckman Coulter).
Absolute numbers of CD34? cells ll
-1 were determined by
usingcalibrationbeads,asrecommendedbythe manufacturer.
EPC quantiﬁcation by cell culture
Blood was diluted 1:1 with PBS, 0.2 M EDTA and overlaid
on Histopaque-1077 (Sigma–Aldrich, Saint-Quentin
Fallavier,France).Cellswerecentrifugedat100gfor20 min.
Mononuclearcells(MNC)werecollectedandwashed3times
in PBS, 0.2 M EDTA. CFU-Hill were cultured with the En-
doCult
 Liquid Medium kit (StemCell Technologies, Van-
couver, BC, Canada) according to the manufacturer’s
instructions. Brieﬂy, MNC were resuspended in complete
EndoCult
 medium and seeded at 5 9 10
6 cells/well in
ﬁbronectin-coated tissue culture plates (BD, Becton–Dick-
inson Biosciences). After 48 h, to obtain CFU-Hill, nonad-
herent cells were collected and plated in Endocult
 buffer at
10
6 cells/well in 24-well ﬁbronectin-coated plates. CFU-Hill
colonies werecountedafter another3 days,asrecommended
by the manufacturer. As previously described [7, 13, 24],
thesecellsdidnotreplicateinvitroandgraduallydisappeared
20 days after plating (Fig. 1b). To obtain ECFC, adherent
cells at 48 h were kept in 6-well ﬁbronectin-coated plates in
EGM2medium(Lonza,Saint-Beauzire,France)composedof
endothelial cell basal medium-2 (EBM2), 5% fetal bovine
serum (FBS) and growth factors. ECFC appeared between 7
and 30 days of culture and consisted of well-circumscribed
cobblestone monolayers (Fig. 1d). Colonies were counted
with an inverted microscope at 920 magniﬁcation. The col-
onieswerethenharvested,trypsinizedandreseededin6-well
plates for complementary studies.
ECFC proliferation assay
After 16 h of serum and growth-factor privation, ECFC
were incubated for 48 h in EBM medium, 5% FBS. Pro-
liferation was examined after 48 h by measuring cell
phosphatase activity based on the release of paranitrophe-
nol (pNPP) (Sigma) measured at OD 405 nm (Fluostar
optima; BMG labtech, Champigny-sur-Marne, France).
Control cells were ECFC from cord blood [6, 25–27].
In vitro matrigel tube formation assay
After 16 h of serum and growth-factor privation, ECFC
(3 9 10
4 cells/well) were seeded on growth factor-reduced
Matrigel (200 ll) (BD Biosciences) in EBM2 medium and
cultured for 18 h at 37C with 5% CO2. Capillary-like
structures were observed by phase-contrast microscopy and
networks formed by ECFC were quantiﬁed with Videomet
software version 5.4.0.
Wound healing assay
A reproducible circular ‘‘wound’’ was made with a tip in
conﬂuent monolayers of ECFC cultured in 12-well plates.
The surface area of the wound was measured at 920 mag-
niﬁcation under an inverted microscope, then the medium
was removed and the cells were further incubated for 4 or
18 hwithEBM,5%FBSandVEGF50 ng/ml.Woundrepair
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after4or18 hofincubationasapercentageoftheinitialarea.
ECFC angiogenic potential in a mouse model
of hind-limb ischemia
Nude mice underwent surgery to induce unilateral hind-
limb ischemia as described elsewhere [6, 28] and were
randomized to receive an intravenous injection of 1 9 10
5
ECFC derived from the two treated patient groups or
1 9 10
5 ECFC derived from cord blood. Two indepen-
dent groups of 20 mice were realized with, in each
experiment, 5 mice injected with PBS, 5 mice with cord
blood ECFC, 5 mice with ECFC from patients with oral
therapy and 5 mice with ECFC from patients with SC-
treprostinil. After 2 weeks, the ischemic/normal limb
Fig. 1 Basal HPC, CFU-Hill and ECFC counts in the children with
PAH. a NUMBER of CD34? hematopoietic progenitor cells (HPC)
determined by FACS analysis. HPC is signiﬁcantly higher in
idiopathic PAH group. b Representative phase-contrast photomicro-
graph of CFU-Hill colony obtained with Endocult
. Note the central
core of rounded cells with spindle-shaped cells sprouting through the
periphery. c Number of CFU-Hill counted with cell culture Endocult

assay. No difference was observed between the different patient
groups. d Representative phase-contrast photomicrograph of an ECFC
colony (mag. 920). e Number of ECFC by cell culture. ECFC is
signiﬁcantly higher in the reversible PAH group
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123blood ﬂow ratio was determined with a laser Doppler
perfusion imaging system.
Statistical analysis
Baseline characteristics were compared between the groups
by using Wilcoxon’s rank sum test for non normally dis-
tributed variables and Student’s unpaired test otherwise.
Student’s paired t test was used to compare progenitor cells
from the same subjects before and after vasodilator treat-
ment. Independent-samples t tests were used to compare
late EPC functional capacity in vitro and in mice. StatView
or SAS statistical software (Cary, NC 27513, USA) was
used for all statistical analyses, and 2-tailed P values below
0.05 were considered to denote signiﬁcant differences.
Results
HPC, CFU-Hill and ECFC counts before treatment
We found no difference in HPC counts between patients
with reversible and irreversible PAH secondary to CHD
[29], while HPC counts were signiﬁcantly higher in
patients with idiopathic PAH (Fig. 1a) (P = 0.02 vs.
patients with reversible PAH and 0.01 vs. patients with
irreversible PAH) in agreement with the data published by
Diller et al. [10]. CFU-Hill counts after 5 days of culture
did not differ across the three patient groups (Fig. 1c). By
contrast, ECFC counts were signiﬁcantly higher in
reversible PAH than in irreversible and idiopathic PAH
(Fig. 1e).
ECFC numbers are increased by prostanoid treatment
No signiﬁcant change in HPC, CFU-Hill and ECFC were
observed when all treated patients versus non treated
patients were compared (Fig. 2a, b, c respectively, with
P = 0.80, 0.89 and 0.15). Oral treatment (monotherapy or
bitherapy) did not modify HPC, CFU-Hill and ECFC
counts count (respectively, P = 0.52, 0.64 and 0.22,
Fig. 3). No change in HPC or CFU-Hill counts (P = 0.76
and P = 0.19, respectively, Fig. 3a, b) were observed after
prostanoid therapy (SC treprostinil), while in contrast, this
led to a signiﬁcant increase in ECFC counts (P = 0.04,
Fig. 3c).
Fig. 2 HPC, CFU-Hill and
ECFC counts in peripheral
venous blood of patients with
pulmonary hypertension, with
and without treatment.
a Number of CD34?
hematopoietic progenitor cells
(HPC) determined by FACS
analysis according to patient
group. No difference is
observed between the treated
and non treated patients
(P = 0.80). b Number of CFU-
Hill colonies determined by cell
culture according to patient
group. No difference is
observed between the treated
and non treated patients
(P = 0.89). c Number of ECFC
determined by cell culture
according to patient group. No
difference is observed between
the treated and non treated
patients (P = 0.15)
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of ECFC
ECFC from patients receiving oral therapy, with or without
SC treprostinil, were grown to conﬂuence from single
colonies. They retained the characteristic cobblestone
aspect through numerous passages and stained positive for
typical endothelial markers CD34, CD146, CD144, PAR-1
thrombin receptor and von Willebrand factor (data not
shown). During the ﬁrst 30 days of culture, cells cultured
from patients receiving oral therapy plus SC treprostinil
showed enhanced proliferation in EBM, 5% FBS compared
to cells from patients receiving only oral therapy (Fig. 4a).
In vitro vascular network formation in Matrigel was similar
with ECFC from patients treated with or without trepros-
tinil (Fig. 4b, c), as was VEGF-induced migration in the
wound healing assay (Fig. 4d, e).
In the preclinical model of hindlimb ischemia, 1 9 10
5
ECFC from each treatment group were injected
Fig. 3 HPC, CFU-Hill and ECFC counts in peripheral venous blood
of patients with pulmonary hypertension according to treatment
subtype. a No difference is observed in HPC according to treatment
subtype (oral mono and/or bitherapy with or without subcutaneous
treprostinil with respectively, a P = 0.52 and 0.76 vs. not treated
PAH). b No difference is observed in CFU-Hill colonies determined
by cell culture according to treatment subtype (oral mono and/or
bitherapy with or without subcutaneous treprostinil with respectively,
a P = 0.64 and 0.19 vs. not treated PAH). c No difference is observed
in ECFC determined by cell culture after oral mono and/or bitherapy
(P = 0.22) while a signiﬁcant increase in ECFC was observed with
subcutaneous treprostinil treatment (* P = 0.04)
Fig. 4 Angiogenic potential of ECFC isolated from patients with
pulmonary hypertension receiving vasodilator treatment. Each patient-
derived ECFC were individually analyzed for proliferation and
angiogenic properties in vitro and in vivo. At least 4 different patients
derived-ECFC were used in each case. a Cells from patients receiving
oral therapy and SC treprostinil showed an increased proliferative
potential (in EBM, 5% FBS) compared with those from patients
receiving oral therapy. Results are presented normalized to ECFC from
cordblood(100%).ThemeanandSEMofthreeexperimentsareshown
P\0.05.b,cECFCisolatedfrompatientsreceiving oraltherapy,with
or without SC treprostinil, form intact vascular networks with similar
efﬁciency. The mean and SEM of three experiments are shown. d,
e VEGF-stimulated migration of ECFC in vitro in a wound healing
assay was similar in patients receiving oral therapy with or without SC
treprostinil. The mean and SEM of three experiments are shown. f,
g ECFC from patients receiving oral therapy, with or without SC
treprostinil, were injected intravenously into nude mice having
undergone femoral artery ligature. Injection of ECFC from patients
receiving oral therapy only improved foot perfusion on day 14 to the
same extent as control ECFC isolated from cord blood. ECFC from
patients receiving oral therapy plus SC treprostinil improved foot
perfusion on day 14 by 25% more than ECFC from patients receiving
oral therapy alone (P = 0.012) and ECFC isolated from cord blood
(P = 0.019)
c
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Injection of ECFC from patients on oral therapy or from
cord blood improved foot perfusion to a similar extent on
day 14, while ECFC from treprostinil-treated patients
improved foot perfusion on day 14 compared to ECFC
from patients on oral therapy without SC treprostinil
(P = 0.012) and ECFC from cord blood (P = 0.019,
Fig. 4f, g).
Discussion
Subcutaneous treprostinil markedly enhanced the number
and functional capacity of ECFC isolated from children
with severe PAH. As these cells are involved in angio-
genesis and endothelial repair, this ﬁnding provides
important insights into the mechanism of action of pros-
tacyclin therapy in this setting.
The endothelium plays a central role in pulmonary vas-
cular regulation, and endothelial dysfunction is increasingly
viewed as critical for disease initiation and progression [3,
30]. We suspected that pharmacological treatment efﬁcacy
could be due, at least in part, to the endothelial repair
capacity of ECFC. Irreversible and idiopathic PAH are
associated with vascular remodeling and with smooth
muscle and endothelial cell proliferation. Plexiform lesions
have a similar histological aspect in idiopathic and irre-
versible PAH. We recently observed neoangiogenesis in
lung surgical biopsy samples from patients with irreversible
PAH due to CHD. This was associated to a proliferative
endothelial phenotype with resistance to apoptosis [4].
These ﬁndings are consistent with a compensatory adaptive
response to increased pulmonary blood ﬂow and arterial
pressure [31, 32], in which ECFC are likely to play an
important role. Standard methods used to assess endothelial
function in the pulmonary circulation are invasive and
complex [33], but recently developed ex vivo evaluations of
endothelial biology have the potential to provide important
insights [34].
Inthepast20 years,pulmonary‘‘vasodilator’’therapyhas
greatly improved the prognosis of patients with PAH [19,
20], it is now clear that these agents do more than simply
dilate pulmonary arterioles. Indeed, such treatments have
been found to enhance revascularization and/or EPC
recruitment in preclinical studies [35–37] and more recently
in patients with critical limb ischemia [38]. Although phos-
phodiesterase 5 (PDE5) inhibitors [39–41] and endothelin
receptor antagonists (ERA) [42–44] improve hemodynamic
parameters,theyhavenotbeenshowntosigniﬁcantlyreduce
mortality of PAH patients, contrary to prostanoids.
This difference between prostanoid, PDE5 inhibitors
and ERA therapy in terms of mortality could result, at least
in part, from a prostanoid-induced enhancement of EPC
numbers and functional capacity, leading to improved
vascular repair and/or new vessel formation. Two clinical
studies recently showed that transplantation of angiogenic
cells improved exercise capacity and pulmonary hemody-
namics in adults and children with idiopathic pulmonary
hypertension [17, 18]. In patients with critical leg ischemia,
we recently showed that bone marrow mononuclear cell
therapy induced the formation of new vessels containing
endothelial cells with a ECFC phenotype [6]. Moreover,
Yoder et al. [7] have shown that transplanted ECFC acquire
a complete endothelial phenotype, maintain a high prolif-
erative potential, and participate in endothelial healing and
angiogenesis. In this study, we showed an increase of foot
perfusion in the preclinical model of hindlimb ischemia of
ECFC isolated from patients treated with treprostinil. Since
human cells are hardly detectable in the muscle vascula-
ture, we cannot exclude a paracrine effect of ECFC isolated
from patients receiving treprostinil. Indeed, ECFC have
been described to secrete several angiogenic pathways that
modulate their ability to increase foot perfusion in this
preclinical model [27].
The main result of our study is that prostanoid therapy
(contrary to PDE5 inhibitors and ERA therapy) increased
the numbers and proliferative capacity of ECFC. ECFC
have been shown to possess all the characteristics of true
endothelial progenitors, based on the clonal relation
between EPC and hematopoietic stem cells in patients with
myeloproliferative disorders. Indeed, ECFC lack disease
markers expressed by early EPC (CFU-Hill or CFU-EC),
supporting the concept that CFU-Hill belong to the
hematopoietic lineage. This suggests that, in patients with
chronic myeloproliferative disorders, ECFC have an origin
distinct from that of the hematopoietic malignant clone [7,
45], and probably have true vasculogenic potential [7].
Here we explored ECFC in prostanoid-treated and -
untreated patients with PAH, a well-characterized vascular
disorder, and found that only ECFC were modiﬁed by
prostanoid treatment, the only therapy shown to reduce
mortality among adults and children with PAH [46–49].
Our results conﬁrm importance of ECFC in PAH. Indeed,
Toshner et al. [22] describe in patients with PAH and
BMPRII mutations that ECFC had a hyperproliferative
phenotype and an impaired capacity to form vascular net-
works, despite an absence of difference in ECFC numbers.
In the present study, CFU-Hill numbers did not differ
between the three groups of patients, and did not change
during treatment. Results of early-EPC or CFU-Hill counts
in PAH are controversial. Asosingh et al. [8] found sig-
niﬁcantly increased numbers of early EPC in PAH patients
compared with controls. In contrast, Junhui et al. [9] found
reduced numbers of early EPC, with functional defects, in
idiopathic PAH patients compared with controls, a ﬁnding
conﬁrmed by Diller et al. [10].
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functional status of ECFC from healthy children. In addi-
tion, we did not attempt to conﬁrm our ﬁndings with
another prostanoid, such as IV prostacyclin, that has also
been shown to improve survival in this setting.
The higher counts and enhanced angiogenic properties
of ECFC in children treated with treprostinil indicate that
these cells could contribute to the compensatory adaptive
response to increased pulmonary blood ﬂow and/or pres-
sure. It is thus tempting to speculate that ECFC expanded
ex vivo might be beneﬁcial in pediatric PAH, especially
given the higher counts and functional capacities of ECFC
in children compared with adults. Indeed, despite the lack
of data on normal ECFC values in children, we found that
the ECFC yield in culture for the two older groups of
children (with idiopathic and irreversible PAH) was similar
to that found in adults [0.2 and 0.6 colonies per 5 9 10
6
MNC, respectively, in irreversible and idiopathic PAH, vs
2.0 in reversible PAH and 0.3 in healthy adults (D. Smadja,
personal data)]. These results are in line with those of
Yoder’s group, who observed a hierarchy of proliferative
potential between cord blood and adult blood. This result
can reasonably be extrapolated to children less than 5 years
old, as was the case of our patients with reversible PAH
(median age 2 years).
In conclusion, this study suggests that prostanoids
enhance the number and proliferative capacities of ECFC
in children with pulmonary hypertension, an effect that
may contribute to endothelial repair and/or new vessel
formation and, thus, to the observed clinical beneﬁts. The
potential interest of ECFC count as a surrogate marker
of prostanoid treatment efﬁcacy is currently being
investigated.
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